Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 56 entries
Sorted by: Best Match Show Resources per page
Effect of high-flow nasal therapy during acute aerobic exercise in patients with chronic obstructive pulmonary disease after exacerbation: protocol for a randomised, controlled, cross-over trial.

BMJ open respiratory research

Prieur G, Medrinal C, Combret Y, Quesada AR, Prieur F, Quieffin J, Borel JC, Reychler G.
PMID: 29071072
BMJ Open Respir Res. 2017 Aug 16;4(1):e000191. doi: 10.1136/bmjresp-2017-000191. eCollection 2017.

INTRODUCTION: Early pulmonary rehabilitation is recommended after a severe exacerbation of chronic obstructive pulmonary disease (COPD). However, this is difficult to implement, particularly for exercise training. High-flow nasal therapy (HFNT) may reduce the work of breathing and dyspnoea and...

Cite
Prieur G, Medrinal C, Combret Y, et al. Effect of high-flow nasal therapy during acute aerobic exercise in patients with chronic obstructive pulmonary disease after exacerbation: protocol for a randomised, controlled, cross-over trial. BMJ Open Respir Res. 2017;4(1):e000191doi: 10.1136/bmjresp-2017-000191.
Prieur, G., Medrinal, C., Combret, Y., Quesada, A. R., Prieur, F., Quieffin, J., Borel, J. C., & Reychler, G. (2017). Effect of high-flow nasal therapy during acute aerobic exercise in patients with chronic obstructive pulmonary disease after exacerbation: protocol for a randomised, controlled, cross-over trial. BMJ open respiratory research, 4(1), e000191. https://doi.org/10.1136/bmjresp-2017-000191
Prieur, Guillaume, et al. "Effect of high-flow nasal therapy during acute aerobic exercise in patients with chronic obstructive pulmonary disease after exacerbation: protocol for a randomised, controlled, cross-over trial." BMJ open respiratory research vol. 4,1 (2017): e000191. doi: https://doi.org/10.1136/bmjresp-2017-000191
Prieur G, Medrinal C, Combret Y, Quesada AR, Prieur F, Quieffin J, Borel JC, Reychler G. Effect of high-flow nasal therapy during acute aerobic exercise in patients with chronic obstructive pulmonary disease after exacerbation: protocol for a randomised, controlled, cross-over trial. BMJ Open Respir Res. 2017 Aug 16;4(1):e000191. doi: 10.1136/bmjresp-2017-000191. eCollection 2017. PMID: 29071072; PMCID: PMC5647475.
Copy Download .nbib Format: NLM
Adenyl cyclase activity in a plasma membrane fraction purified from "ghosts" of rat fat cells.

FEBS letters

Combret Y, Laudat P.
PMID: 11946471
FEBS Lett. 1972 Mar;21(1):45-48. doi: 10.1016/0014-5793(72)80159-5.

No abstract available.

Cite
Combret Y, Laudat P. Adenyl cyclase activity in a plasma membrane fraction purified from "ghosts" of rat fat cells. FEBS Lett. 1972;21(1):45-48doi: 10.1016/0014-5793(72)80159-5.
Combret, Y., & Laudat, P. (1972). Adenyl cyclase activity in a plasma membrane fraction purified from "ghosts" of rat fat cells. FEBS letters, 21(1), 45-48. https://doi.org/10.1016/0014-5793(72)80159-5
Combret, Y, and Laudat, P. "Adenyl cyclase activity in a plasma membrane fraction purified from "ghosts" of rat fat cells." FEBS letters vol. 21,1 (1972): 45-48. doi: https://doi.org/10.1016/0014-5793(72)80159-5
Combret Y, Laudat P. Adenyl cyclase activity in a plasma membrane fraction purified from "ghosts" of rat fat cells. FEBS Lett. 1972 Mar;21(1):45-48. doi: 10.1016/0014-5793(72)80159-5. PMID: 11946471.
Copy Download .nbib Format: NLM
A moiré deflectometer for antimatter.

Nature communications

Aghion S, Ahlén O, Amsler C, Ariga A, Ariga T, Belov AS, Berggren K, Bonomi G, Bräunig P, Bremer J, Brusa RS, Cabaret L, Canali C, Caravita R, Castelli F, Cerchiari G, Cialdi S, Comparat D, Consolati G, Derking H, Di Domizio S, Di Noto L, Doser M, Dudarev A, Ereditato A, Ferragut R, Fontana A, Genova P, Giammarchi M, Gligorova A, Gninenko SN, Haider S, Huse T, Jordan E, Jørgensen LV, Kaltenbacher T, Kawada J, Kellerbauer A, Kimura M, Knecht A, Krasnický D, Lagomarsino V, Lehner S, Magnani A, Malbrunot C, Mariazzi S, Matveev VA, Moia F, Nebbia G, Nédélec P, Oberthaler MK, Pacifico N, Petràček V, Pistillo C, Prelz F, Prevedelli M, Regenfus C, Riccardi C, Røhne O, Rotondi A, Sandaker H, Scampoli P, Storey J, Vasquez MA, Špaček M, Testera G, Vaccarone R, Widmann E, Zavatarelli S, Zmeskal J.
PMID: 25066810
Nat Commun. 2014 Jul 28;5:4538. doi: 10.1038/ncomms5538.

The precise measurement of forces is one way to obtain deep insight into the fundamental interactions present in nature. In the context of neutral antimatter, the gravitational interaction is of high interest, potentially revealing new forces that violate the...

Cite
Aghion S, Ahlén O, Amsler C, et al. A moiré deflectometer for antimatter. Nat Commun. 2014;5:4538doi: 10.1038/ncomms5538.
Aghion, S., Ahlén, O., Amsler, C., Ariga, A., Ariga, T., Belov, A. S., Berggren, K., Bonomi, G., Bräunig, P., Bremer, J., Brusa, R. S., Cabaret, L., Canali, C., Caravita, R., Castelli, F., Cerchiari, G., Cialdi, S., Comparat, D., Consolati, G., Derking, H., Di Domizio, S., Di Noto, L., Doser, M., Dudarev, A., Ereditato, A., Ferragut, R., Fontana, A., Genova, P., Giammarchi, M., Gligorova, A., Gninenko, S. N., Haider, S., Huse, T., Jordan, E., Jørgensen, L. V., Kaltenbacher, T., Kawada, J., Kellerbauer, A., Kimura, M., Knecht, A., Krasnický, D., Lagomarsino, V., Lehner, S., Magnani, A., Malbrunot, C., Mariazzi, S., Matveev, V. A., Moia, F., Nebbia, G., Nédélec, P., Oberthaler, M. K., Pacifico, N., Petràček, V., Pistillo, C., Prelz, F., Prevedelli, M., Regenfus, C., Riccardi, C., Røhne, O., Rotondi, A., Sandaker, H., Scampoli, P., Storey, J., Vasquez, M. A., Špaček, M., Testera, G., Vaccarone, R., Widmann, E., Zavatarelli, S., & Zmeskal, J. (2014). A moiré deflectometer for antimatter. Nature communications, 54538. https://doi.org/10.1038/ncomms5538
Aghion, S, et al. "A moiré deflectometer for antimatter." Nature communications vol. 5 (2014): 4538. doi: https://doi.org/10.1038/ncomms5538
Aghion S, Ahlén O, Amsler C, Ariga A, Ariga T, Belov AS, Berggren K, Bonomi G, Bräunig P, Bremer J, Brusa RS, Cabaret L, Canali C, Caravita R, Castelli F, Cerchiari G, Cialdi S, Comparat D, Consolati G, Derking H, Di Domizio S, Di Noto L, Doser M, Dudarev A, Ereditato A, Ferragut R, Fontana A, Genova P, Giammarchi M, Gligorova A, Gninenko SN, Haider S, Huse T, Jordan E, Jørgensen LV, Kaltenbacher T, Kawada J, Kellerbauer A, Kimura M, Knecht A, Krasnický D, Lagomarsino V, Lehner S, Magnani A, Malbrunot C, Mariazzi S, Matveev VA, Moia F, Nebbia G, Nédélec P, Oberthaler MK, Pacifico N, Petràček V, Pistillo C, Prelz F, Prevedelli M, Regenfus C, Riccardi C, Røhne O, Rotondi A, Sandaker H, Scampoli P, Storey J, Vasquez MA, Špaček M, Testera G, Vaccarone R, Widmann E, Zavatarelli S, Zmeskal J. A moiré deflectometer for antimatter. Nat Commun. 2014 Jul 28;5:4538. doi: 10.1038/ncomms5538. PMID: 25066810; PMCID: PMC4124857.
Copy Download .nbib Format: NLM
Experimental evidence for subradiance.

Physical review letters

Cabaret L, Crubellier A, Liberman S, Pavolini D, Pillet P.
PMID: 10031175
Phys Rev Lett. 1985 Apr 29;54(17):1917-1920. doi: 10.1103/PhysRevLett.54.1917.

No abstract available.

Cite
Cabaret L, Crubellier A, Liberman S, et al. Experimental evidence for subradiance. Phys Rev Lett. 1985;54(17):1917-1920doi: 10.1103/PhysRevLett.54.1917.
Cabaret, L., Crubellier, A., Liberman, S., Pavolini, D., & Pillet, P. (1985). Experimental evidence for subradiance. Physical review letters, 54(17), 1917-1920. https://doi.org/10.1103/PhysRevLett.54.1917
Cabaret, et al. "Experimental evidence for subradiance." Physical review letters vol. 54,17 (1985): 1917-1920. doi: https://doi.org/10.1103/PhysRevLett.54.1917
Cabaret L, Crubellier A, Liberman S, Pavolini D, Pillet P. Experimental evidence for subradiance. Phys Rev Lett. 1985 Apr 29;54(17):1917-1920. doi: 10.1103/PhysRevLett.54.1917. PMID: 10031175.
Copy Download .nbib Format: NLM
UBE2E1 Is Preferentially Expressed in the Cytoplasm of Slow-Twitch Fibers and Protects Skeletal Muscles from Exacerbated Atrophy upon Dexamethasone Treatment.

Cells

Cécile P, Julien A, Andrea A, Agnès C, Cécile CG, Clara T, Christiane D, Lydie C, Daniel B, Marco S, Didier A, Daniel T.
PMID: 30453501
Cells. 2018 Nov 16;7(11). doi: 10.3390/cells7110214.

Skeletal muscle mass is reduced during many diseases or physiological situations (disuse, aging), which results in decreased strength and increased mortality. Muscle mass is mainly controlled by the ubiquitin-proteasome system (UPS), involving hundreds of ubiquitinating enzymes (E2s and E3s)...

Cite
Cécile P, Julien A, Andrea A, et al. UBE2E1 Is Preferentially Expressed in the Cytoplasm of Slow-Twitch Fibers and Protects Skeletal Muscles from Exacerbated Atrophy upon Dexamethasone Treatment. Cells. 2018;7(11)doi: 10.3390/cells7110214.
Cécile, P., Julien, A., Andrea, A., Agnès, C., Cécile, C. G., Clara, T., Christiane, D., Lydie, C., Daniel, B., Marco, S., Didier, A., & Daniel, T. (2018). UBE2E1 Is Preferentially Expressed in the Cytoplasm of Slow-Twitch Fibers and Protects Skeletal Muscles from Exacerbated Atrophy upon Dexamethasone Treatment. Cells, 7(11), . https://doi.org/10.3390/cells7110214
Cécile, Polge, et al. "UBE2E1 Is Preferentially Expressed in the Cytoplasm of Slow-Twitch Fibers and Protects Skeletal Muscles from Exacerbated Atrophy upon Dexamethasone Treatment." Cells vol. 7,11 (2018). doi: https://doi.org/10.3390/cells7110214
Cécile P, Julien A, Andrea A, Agnès C, Cécile CG, Clara T, Christiane D, Lydie C, Daniel B, Marco S, Didier A, Daniel T. UBE2E1 Is Preferentially Expressed in the Cytoplasm of Slow-Twitch Fibers and Protects Skeletal Muscles from Exacerbated Atrophy upon Dexamethasone Treatment. Cells. 2018 Nov 16;7(11). doi: 10.3390/cells7110214. PMID: 30453501; PMCID: PMC6262581.
Copy Download .nbib Format: NLM
The NLRP3 p.A441V Mutation in .

ACR open rheumatology

Awad F, Assrawi E, Jumeau C, Odent S, Despert V, Cam G, Perdriger A, Louvrier C, Cobret L, Copin B, Chantot-Bastaraud S, Duquesnoy P, Piterboth W, Le Jeunne C, Quenum-Miraillet G, Siffroi JP, Georgin-Lavialle S, Grateau G, Legendre M, Giurgea I, Karabina SA, Amselem S.
PMID: 31777803
ACR Open Rheumatol. 2019 Jun 06;1(4):267-276. doi: 10.1002/acr2.1039. eCollection 2019 Jun.

OBJECTIVE: To determine the molecular and cellular bases of autoinflammatory syndromes in a multigenerational French family with Muckle-Wells syndrome and in a patient originating from Portugal with familial cold autoinflammatory syndrome.METHODS: Sequencing of RESULTS: The same heterozygous mutation (c.1322C>T,...

Cite
Awad F, Assrawi E, Jumeau C, et al. The NLRP3 p.A441V Mutation in . ACR Open Rheumatol. 2019;1(4):267-276doi: 10.1002/acr2.1039.
Awad, F., Assrawi, E., Jumeau, C., Odent, S., Despert, V., Cam, G., Perdriger, A., Louvrier, C., Cobret, L., Copin, B., Chantot-Bastaraud, S., Duquesnoy, P., Piterboth, W., Le Jeunne, C., Quenum-Miraillet, G., Siffroi, J. P., Georgin-Lavialle, S., Grateau, G., Legendre, M., Giurgea, I., Karabina, S. A., & Amselem, S. (2019). The NLRP3 p.A441V Mutation in . ACR open rheumatology, 1(4), 267-276. https://doi.org/10.1002/acr2.1039
Awad, Fawaz, et al. "The NLRP3 p.A441V Mutation in ." ACR open rheumatology vol. 1,4 (2019): 267-276. doi: https://doi.org/10.1002/acr2.1039
Awad F, Assrawi E, Jumeau C, Odent S, Despert V, Cam G, Perdriger A, Louvrier C, Cobret L, Copin B, Chantot-Bastaraud S, Duquesnoy P, Piterboth W, Le Jeunne C, Quenum-Miraillet G, Siffroi JP, Georgin-Lavialle S, Grateau G, Legendre M, Giurgea I, Karabina SA, Amselem S. The NLRP3 p.A441V Mutation in . ACR Open Rheumatol. 2019 Jun 06;1(4):267-276. doi: 10.1002/acr2.1039. eCollection 2019 Jun. PMID: 31777803; PMCID: PMC6857991.
Copy Download .nbib Format: NLM
Validity and reliability of the one-minute sit-to-stand test for the measurement of cardio-respiratory responses in children with cystic fibrosis.

Pulmonology

Combret Y, Prieur G, Boujibar F, Gravier FE, Smondack P, Le Roux P, Bonnevie T, Medrinal C, Reychler G.
PMID: 34844914
Pulmonology. 2021 Nov 26; doi: 10.1016/j.pulmoe.2021.10.005. Epub 2021 Nov 26.

No abstract available.

Cite
Combret Y, Prieur G, Boujibar F, et al. Validity and reliability of the one-minute sit-to-stand test for the measurement of cardio-respiratory responses in children with cystic fibrosis. Pulmonology. 2021;doi: 10.1016/j.pulmoe.2021.10.005.
Combret, Y., Prieur, G., Boujibar, F., Gravier, F. E., Smondack, P., Le Roux, P., Bonnevie, T., Medrinal, C., & Reychler, G. (2021). Validity and reliability of the one-minute sit-to-stand test for the measurement of cardio-respiratory responses in children with cystic fibrosis. Pulmonology, . https://doi.org/10.1016/j.pulmoe.2021.10.005
Combret, Yann, et al. "Validity and reliability of the one-minute sit-to-stand test for the measurement of cardio-respiratory responses in children with cystic fibrosis." Pulmonology vol. (2021). doi: https://doi.org/10.1016/j.pulmoe.2021.10.005
Combret Y, Prieur G, Boujibar F, Gravier FE, Smondack P, Le Roux P, Bonnevie T, Medrinal C, Reychler G. Validity and reliability of the one-minute sit-to-stand test for the measurement of cardio-respiratory responses in children with cystic fibrosis. Pulmonology. 2021 Nov 26; doi: 10.1016/j.pulmoe.2021.10.005. Epub 2021 Nov 26. PMID: 34844914.
Copy Download .nbib Format: NLM
Sarcopenia in patients after an episode of acute decompensated heart failure: An underdiagnosed problem with serious impact.

Clinical nutrition (Edinburgh, Scotland)

Eschalier R, Massoullié G, Boirie Y, Blanquet M, Mulliez A, Tartière PL, Anker S, D'Agrosa Boiteux MC, Richard R, Jean F, Combaret N, Souteyrand G, Riocreux C, Pereira B, Motreff P, Stolt P, Rossignol P, Clerfond G.
PMID: 33483182
Clin Nutr. 2021 Jun;40(6):4490-4499. doi: 10.1016/j.clnu.2020.12.033. Epub 2021 Jan 09.

BACKGROUND & AIMS: Sarcopenia is a multifactorial syndrome resulting in a decrease in both muscle mass and function. Little is known about the prevalence and prognostic impact of sarcopenia in patients with acutely decompensated chronic heart failure (ADHF). We...

Cite
Eschalier R, Massoullié G, Boirie Y, et al. Sarcopenia in patients after an episode of acute decompensated heart failure: An underdiagnosed problem with serious impact. Clin Nutr. 2021;40(6):4490-4499doi: 10.1016/j.clnu.2020.12.033.
Eschalier, R., Massoullié, G., Boirie, Y., Blanquet, M., Mulliez, A., Tartière, P. L., Anker, S., D'Agrosa Boiteux, M. C., Richard, R., Jean, F., Combaret, N., Souteyrand, G., Riocreux, C., Pereira, B., Motreff, P., Stolt, P., Rossignol, P., & Clerfond, G. (2021). Sarcopenia in patients after an episode of acute decompensated heart failure: An underdiagnosed problem with serious impact. Clinical nutrition (Edinburgh, Scotland), 40(6), 4490-4499. https://doi.org/10.1016/j.clnu.2020.12.033
Eschalier, Romain, et al. "Sarcopenia in patients after an episode of acute decompensated heart failure: An underdiagnosed problem with serious impact." Clinical nutrition (Edinburgh, Scotland) vol. 40,6 (2021): 4490-4499. doi: https://doi.org/10.1016/j.clnu.2020.12.033
Eschalier R, Massoullié G, Boirie Y, Blanquet M, Mulliez A, Tartière PL, Anker S, D'Agrosa Boiteux MC, Richard R, Jean F, Combaret N, Souteyrand G, Riocreux C, Pereira B, Motreff P, Stolt P, Rossignol P, Clerfond G. Sarcopenia in patients after an episode of acute decompensated heart failure: An underdiagnosed problem with serious impact. Clin Nutr. 2021 Jun;40(6):4490-4499. doi: 10.1016/j.clnu.2020.12.033. Epub 2021 Jan 09. PMID: 33483182.
Copy Download .nbib Format: NLM
Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics study.

ESMO open

Cerbone L, Combarel D, Geraud A, Auclin E, Foulon S, Alves Costa Silva C, Colomba E, Carril L, Derosa L, Flippot R, Mir O, Khoudour N, Blanchet B, Escudier B, Paci A, Albiges L.
PMID: 34864351
ESMO Open. 2021 Dec;6(6):100312. doi: 10.1016/j.esmoop.2021.100312. Epub 2021 Dec 01.

BACKGROUND: Cabozantinib is a tyrosine kinase inhibitor with a substantial efficacy in metastatic renal cell carcinoma, and is associated with a challenging toxicity profile leading to frequent drug discontinuations. Whereas an exposure/safety relationship was demonstrated for this drug, an...

Cite
Cerbone L, Combarel D, Geraud A, et al. Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics study. ESMO Open. 2021;6(6):100312doi: 10.1016/j.esmoop.2021.100312.
Cerbone, L., Combarel, D., Geraud, A., Auclin, E., Foulon, S., Alves Costa Silva, C., Colomba, E., Carril, L., Derosa, L., Flippot, R., Mir, O., Khoudour, N., Blanchet, B., Escudier, B., Paci, A., & Albiges, L. (2021). Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics study. ESMO open, 6(6), 100312. https://doi.org/10.1016/j.esmoop.2021.100312
Cerbone, L, et al. "Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics study." ESMO open vol. 6,6 (2021): 100312. doi: https://doi.org/10.1016/j.esmoop.2021.100312
Cerbone L, Combarel D, Geraud A, Auclin E, Foulon S, Alves Costa Silva C, Colomba E, Carril L, Derosa L, Flippot R, Mir O, Khoudour N, Blanchet B, Escudier B, Paci A, Albiges L. Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics study. ESMO Open. 2021 Dec;6(6):100312. doi: 10.1016/j.esmoop.2021.100312. Epub 2021 Dec 01. PMID: 34864351; PMCID: PMC8645912.
Copy Download .nbib Format: NLM
Comparison of oxygen uptake during cycle ergometry with and without functional electrical stimulation in patients with COPD: protocol for a randomised, single-blind, placebo-controlled, cross-over trial.

BMJ open respiratory research

Medrinal C, Prieur G, Debeaumont D, Robledo Quesada A, Combret Y, Quieffin J, Contal O, Lamia B.
PMID: 27110364
BMJ Open Respir Res. 2016 Apr 12;3(1):e000130. doi: 10.1136/bmjresp-2016-000130. eCollection 2016.

INTRODUCTION: Chronic obstructive pulmonary disease (COPD) has systemic repercussions that can lead to peripheral muscle dysfunction. Muscle atrophy reduces aerobic capacity, greatly limiting activities of daily living and quality of life. Pulmonary rehabilitation is the gold standard treatment for...

Cite
Medrinal C, Prieur G, Debeaumont D, et al. Comparison of oxygen uptake during cycle ergometry with and without functional electrical stimulation in patients with COPD: protocol for a randomised, single-blind, placebo-controlled, cross-over trial. BMJ Open Respir Res. 2016;3(1):e000130doi: 10.1136/bmjresp-2016-000130.
Medrinal, C., Prieur, G., Debeaumont, D., Robledo Quesada, A., Combret, Y., Quieffin, J., Contal, O., & Lamia, B. (2016). Comparison of oxygen uptake during cycle ergometry with and without functional electrical stimulation in patients with COPD: protocol for a randomised, single-blind, placebo-controlled, cross-over trial. BMJ open respiratory research, 3(1), e000130. https://doi.org/10.1136/bmjresp-2016-000130
Medrinal, Clément, et al. "Comparison of oxygen uptake during cycle ergometry with and without functional electrical stimulation in patients with COPD: protocol for a randomised, single-blind, placebo-controlled, cross-over trial." BMJ open respiratory research vol. 3,1 (2016): e000130. doi: https://doi.org/10.1136/bmjresp-2016-000130
Medrinal C, Prieur G, Debeaumont D, Robledo Quesada A, Combret Y, Quieffin J, Contal O, Lamia B. Comparison of oxygen uptake during cycle ergometry with and without functional electrical stimulation in patients with COPD: protocol for a randomised, single-blind, placebo-controlled, cross-over trial. BMJ Open Respir Res. 2016 Apr 12;3(1):e000130. doi: 10.1136/bmjresp-2016-000130. eCollection 2016. PMID: 27110364; PMCID: PMC4838753.
Copy Download .nbib Format: NLM
Baseline characteristics, management, and predictors of early mortality in cardiogenic shock: insights from the FRENSHOCK registry.

ESC heart failure

Delmas C, Roubille F, Lamblin N, Bonello L, Leurent G, Levy B, Elbaz M, Danchin N, Champion S, Lim P, Schneider F, Cariou A, Khachab H, Bourenne J, Seronde MF, Schurtz G, Harbaoui B, Vanzetto G, Quentin C, Delabranche X, Aissaoui N, Combaret N, Manzo-Silberman S, Tomasevic D, Marchandot B, Lattuca B, Henry P, Gerbaud E, Bonnefoy E, Puymirat E.
PMID: 34973047
ESC Heart Fail. 2021 Dec 31; doi: 10.1002/ehf2.13734. Epub 2021 Dec 31.

AIMS: Published data on cardiogenic shock (CS) are scarce and are mostly focused on small registries of selected populations. The aim of this study was to examine the current CS picture and define the independent correlates of 30 day...

Cite
Delmas C, Roubille F, Lamblin N, et al. Baseline characteristics, management, and predictors of early mortality in cardiogenic shock: insights from the FRENSHOCK registry. ESC Heart Fail. 2021;doi: 10.1002/ehf2.13734.
Delmas, C., Roubille, F., Lamblin, N., Bonello, L., Leurent, G., Levy, B., Elbaz, M., Danchin, N., Champion, S., Lim, P., Schneider, F., Cariou, A., Khachab, H., Bourenne, J., Seronde, M. F., Schurtz, G., Harbaoui, B., Vanzetto, G., Quentin, C., Delabranche, X., Aissaoui, N., Combaret, N., Manzo-Silberman, S., Tomasevic, D., Marchandot, B., Lattuca, B., Henry, P., Gerbaud, E., Bonnefoy, E., & Puymirat, E. (2021). Baseline characteristics, management, and predictors of early mortality in cardiogenic shock: insights from the FRENSHOCK registry. ESC heart failure, . https://doi.org/10.1002/ehf2.13734
Delmas, Clement, et al. "Baseline characteristics, management, and predictors of early mortality in cardiogenic shock: insights from the FRENSHOCK registry." ESC heart failure vol. (2021). doi: https://doi.org/10.1002/ehf2.13734
Delmas C, Roubille F, Lamblin N, Bonello L, Leurent G, Levy B, Elbaz M, Danchin N, Champion S, Lim P, Schneider F, Cariou A, Khachab H, Bourenne J, Seronde MF, Schurtz G, Harbaoui B, Vanzetto G, Quentin C, Delabranche X, Aissaoui N, Combaret N, Manzo-Silberman S, Tomasevic D, Marchandot B, Lattuca B, Henry P, Gerbaud E, Bonnefoy E, Puymirat E. Baseline characteristics, management, and predictors of early mortality in cardiogenic shock: insights from the FRENSHOCK registry. ESC Heart Fail. 2021 Dec 31; doi: 10.1002/ehf2.13734. Epub 2021 Dec 31. PMID: 34973047.
Copy Download .nbib Format: NLM
Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics study.

ESMO open

Cerbone L, Combarel D, Geraud A, Auclin E, Foulon S, Alves Costa Silva C, Colomba E, Carril L, Derosa L, Flippot R, Mir O, Khoudour N, Blanchet B, Escudier B, Paci A, Albiges L.
PMID: 34864351
ESMO Open. 2021 Dec 01;6(6):100312. doi: 10.1016/j.esmoop.2021.100312. Epub 2021 Dec 01.

BACKGROUND: Cabozantinib is a tyrosine kinase inhibitor with a substantial efficacy in metastatic renal cell carcinoma, and is associated with a challenging toxicity profile leading to frequent drug discontinuations. Whereas an exposure/safety relationship was demonstrated for this drug, an...

Cite
Cerbone L, Combarel D, Geraud A, et al. Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics study. ESMO Open. 2021;6(6):100312doi: 10.1016/j.esmoop.2021.100312.
Cerbone, L., Combarel, D., Geraud, A., Auclin, E., Foulon, S., Alves Costa Silva, C., Colomba, E., Carril, L., Derosa, L., Flippot, R., Mir, O., Khoudour, N., Blanchet, B., Escudier, B., Paci, A., & Albiges, L. (2021). Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics study. ESMO open, 6(6), 100312. https://doi.org/10.1016/j.esmoop.2021.100312
Cerbone, L, et al. "Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics study." ESMO open vol. 6,6 (2021): 100312. doi: https://doi.org/10.1016/j.esmoop.2021.100312
Cerbone L, Combarel D, Geraud A, Auclin E, Foulon S, Alves Costa Silva C, Colomba E, Carril L, Derosa L, Flippot R, Mir O, Khoudour N, Blanchet B, Escudier B, Paci A, Albiges L. Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics study. ESMO Open. 2021 Dec 01;6(6):100312. doi: 10.1016/j.esmoop.2021.100312. Epub 2021 Dec 01. PMID: 34864351.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 56 entries